Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 25, 2007

Eisai to Continue Support of TorreyPines’ Alzheimer’s Target Discovery Work

  • TorreyPines Therapeutics and Eisai extended their collaboration related to discovery of Alzheimer’s targets by a year. The goal of the genetics research is to identify and validate genes associated with the disease.

    Under the terms of the agreement and in connection with the extension, TorreyPines will receive an upfront payment and continued research funding. Eisai will continue to have exclusive rights of first negotiation and refusal for gene targets discovered and validated through the research.

    The companies have a separate partnership to find compounds to treat Alzheimer’s, which was also recently extended.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »